For adult patients with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) when other therapies have not worked well enough or cannot be tolerated.
Request a Rep
If you’d like to learn more information about ENTYVIO for the treatment of moderate to severe ulcerative colitis or Crohn’s disease, fill out the form below to connect with a Clinical Sales Specialist.
IMPORTANT SAFETY INFORMATION
Contraindications
WARNINGS AND PRECAUTIONS
IMPORTANT SAFETY INFORMATION
Contraindications
ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
Warnings and precautions
Adverse reactions
The most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) were: nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities, and injection site reactions with subcutaneous administration.
Drug interactions
Because of the potential for increased risk of PML and other infections, avoid the concomitant use of ENTYVIO with natalizumab products and with TNF blockers.
INDICATIONS
Adult Ulcerative Colitis (UC):
ENTYVIO is indicated in adults for the treatment of moderately to severely active UC.
Adult Crohn’s Disease (CD):
ENTYVIO is indicated in adults for the treatment of moderately to severely active CD.
Dosage forms & strengths:
Please click for Full Prescribing Information.